AAPL   376.56 (+0.72%)
MSFT   212.34 (+0.78%)
GOOGL   1,512.98 (+0.89%)
NVDA   398.81 (+1.33%)
CGC   16.55 (-2.30%)
BABA   237.97 (-0.85%)
GE   6.81 (-2.86%)
TSLA   1,398.08 (+1.93%)
ACB   12.24 (+0.49%)
DIS   113.39 (-0.90%)
BAC   23.07 (-2.49%)
NFLX   494.40 (+0.12%)
AAPL   376.56 (+0.72%)
MSFT   212.34 (+0.78%)
GOOGL   1,512.98 (+0.89%)
NVDA   398.81 (+1.33%)
CGC   16.55 (-2.30%)
BABA   237.97 (-0.85%)
GE   6.81 (-2.86%)
TSLA   1,398.08 (+1.93%)
ACB   12.24 (+0.49%)
DIS   113.39 (-0.90%)
BAC   23.07 (-2.49%)
NFLX   494.40 (+0.12%)
AAPL   376.56 (+0.72%)
MSFT   212.34 (+0.78%)
GOOGL   1,512.98 (+0.89%)
NVDA   398.81 (+1.33%)
CGC   16.55 (-2.30%)
BABA   237.97 (-0.85%)
GE   6.81 (-2.86%)
TSLA   1,398.08 (+1.93%)
ACB   12.24 (+0.49%)
DIS   113.39 (-0.90%)
BAC   23.07 (-2.49%)
NFLX   494.40 (+0.12%)
AAPL   376.56 (+0.72%)
MSFT   212.34 (+0.78%)
GOOGL   1,512.98 (+0.89%)
NVDA   398.81 (+1.33%)
CGC   16.55 (-2.30%)
BABA   237.97 (-0.85%)
GE   6.81 (-2.86%)
TSLA   1,398.08 (+1.93%)
ACB   12.24 (+0.49%)
DIS   113.39 (-0.90%)
BAC   23.07 (-2.49%)
NFLX   494.40 (+0.12%)
Log in

NASDAQ:STIMNeuronetics Stock Price, Forecast & News

$1.91
+0.04 (+2.14 %)
(As of 07/7/2020 12:19 PM ET)
Add
Compare
Today's Range
$1.80
Now: $1.91
$1.91
50-Day Range
$1.82
MA: $1.96
$2.29
52-Week Range
$1.25
Now: $1.91
$13.31
Volume4,145 shs
Average Volume1.33 million shs
Market Capitalization$35.77 million
P/E RatioN/A
Dividend YieldN/A
Beta1.48
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrist customers. Neuronetics, Inc. was founded in 2003 and is headquartered in Malvern, Pennsylvania.
Read More
Neuronetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.65 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STIM
CUSIPN/A
CIKN/A
Phone610-640-4202

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$62.66 million
Book Value$2.57 per share

Profitability

Net Income$-29,040,000.00

Miscellaneous

Employees191
Market Cap$35.77 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive STIM News and Ratings via Email

Sign-up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter.

Neuronetics (NASDAQ:STIM) Frequently Asked Questions

How has Neuronetics' stock been impacted by COVID-19 (Coronavirus)?

Neuronetics' stock was trading at $2.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, STIM shares have decreased by 7.7% and is now trading at $1.91. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Neuronetics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neuronetics.

When is Neuronetics' next earnings date?

Neuronetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Neuronetics.

How were Neuronetics' earnings last quarter?

Neuronetics Inc (NASDAQ:STIM) issued its quarterly earnings results on Tuesday, May, 5th. The company reported ($0.63) EPS for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.13. The company had revenue of $11.48 million for the quarter. Neuronetics had a negative return on equity of 68.77% and a negative net margin of 55.58%. View Neuronetics' earnings history.

What guidance has Neuronetics issued on next quarter's earnings?

Neuronetics updated its first quarter 2020 After-Hours earnings guidance on Wednesday, April, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $11.8-12 million, compared to the consensus revenue estimate of $13.77 million.

What price target have analysts set for STIM?

4 brokers have issued twelve-month price targets for Neuronetics' stock. Their forecasts range from $4.00 to $6.00. On average, they anticipate Neuronetics' stock price to reach $5.33 in the next twelve months. This suggests a possible upside of 179.2% from the stock's current price. View analysts' price targets for Neuronetics.

Has Neuronetics been receiving favorable news coverage?

Media headlines about STIM stock have been trending negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Neuronetics earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Neuronetics.

Are investors shorting Neuronetics?

Neuronetics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 825,200 shares, an increase of 13.3% from the June 15th total of 728,400 shares. Based on an average trading volume of 546,500 shares, the short-interest ratio is currently 1.5 days. Approximately 7.7% of the shares of the company are sold short. View Neuronetics' Current Options Chain.

Who are some of Neuronetics' key competitors?

What other stocks do shareholders of Neuronetics own?

Who are Neuronetics' key executives?

Neuronetics' management team includes the following people:
  • Mr. Christopher A. Thatcher, CEO, Pres & Director (Age 54)
  • Mr. Peter L. Donato, CFO, VP & Corp. Sec. (Age 49)
  • Mr. Gregory Harper, VP of R&D, Operations and Product Devel. (Age 58)
  • Ms. Cassie Hallberg, VP of Marketing
  • Mr. Daniel Guthrie, Chief Commercial Officer & VP (Age 42)

When did Neuronetics IPO?

(STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

What is Neuronetics' stock symbol?

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

How do I buy shares of Neuronetics?

Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neuronetics' stock price today?

One share of STIM stock can currently be purchased for approximately $1.91.

How big of a company is Neuronetics?

Neuronetics has a market capitalization of $35.77 million and generates $62.66 million in revenue each year. The company earns $-29,040,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Neuronetics employs 191 workers across the globe.

What is Neuronetics' official website?

The official website for Neuronetics is www.neurostar.com.

How can I contact Neuronetics?

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected]

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.